Sun Pharma announces approval to mkt Exelon capsules

2441 Investors following Novartis India. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma announces approval to mkt Exelon capsules

Sun Pharma announces USFDA approval to market generic Exelon® capsules

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy follows Sun Pharma in demerging R&D biz Sun Pharma gets “will-not-sue” covenant on Effexor XR ANDA Buy Sun Pharma, target Rs 1287: Sharekhan Sun Pharma gets approval to market generic Trileptal tabets ALSO READ See latest News about Novartis India See previous management interviews See what other Experts & Brokerages are saying about Novartis India Novartis India BSE | NSE 01/01/70 Are Mutual Funds betting on Novartis India? Other Stocks in this news Sun Pharmaceutical Industries |

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis Exelon®, rivastigmine tartrate capsules.

These generic rivastigmine capsules are AB-rated equivalent of Novartis Exelon® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 200 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon® with a para IV certification, shares a 180- day marketing exclusivity. In view of the ongoing litigation with Novartis on this product, the Company is evaluating all its launch options.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease. 

Sourced From: Sun Pharmaceutical Industries Ltd